Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.

Thomas J HerzogShaun A WahabMansoor Raza Mirza Bhavana PothuriIgnace VergoteWhitney S GraybillIzabela A MalinowskaWhitney YorkJean A HurteauDivya GuptaAntonio Gonzáles Martin Bradley J Monk

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

PRIMA/ENGOT-ov26/GOG-3012 highlights the need to optimize blinded independent centralized review and investigator concordance using early, specialized, ovarian-cancer-specific radiology training to maximize validity of outcome data.

Keyphrases

study protocol
clinical trial
palliative care
artificial intelligence
placebo controlled
phase iii
big data
phase ii
deep learning
data analysis